Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELEAF-TAVI edoxaban leaflet thickening study
NL-OMON52528Phase 3Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of edoxaban in aortic stenosis (AS), sponsored by Erasmus MC. Primary endpoint: Incidence of aortic valve leaflet thickening. Started Aug 2019; status: active, not recruiting.
02
Drugs
edoxaban
03
Conditions
aortic stenosis (AS)
Beyond the preview
Go deeper on NL-OMON52528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52528.